semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) Participants will have: 1. a diagnosis of COPD which is clinically stable (including medications) for at least one month; 2. spirometry results showing at least mild obstructive disease defined as post bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio <0.70 with FEV1<80% predicted or post-bronchodilator FEV1/FVC ratio <0.60 with FEV1>80% predicted; 3. ADL limited by dyspnea; 4. a designated primary care physician; 5. ability to speak English and sign consent form; 6. actively using a computer and the Internet; 7. no formal pulmonary rehabilitation training for at least 12 months; 8. patients receiving supplemental oxygen will be acceptable if their O2 saturation can be maintained at >80% on <6L/min of nasal oxygen; 9. understands how to and is able to rate their shortness of breath during exercise; 10. age > 40 years  Subjects will be excluded if they have active symptomatic illness (e.g., cancer, left heart failure, ischemic heart disease with known coronary artery or valvular heart disease, psychiatric illness, and neuromuscular disease)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Cholesterol, LDL Black, white and hispanic males between the ages of 20 to 70 years In good general health Having a body mass index (BMI) between 20 and 35 kg/m2 Plasma LDL-C concentrations greater than or equal to 130 mg/dl but less than or equal to 175 mg/dL TG (triglyceride) levels less than or equal to 250 mg/dL  Any condition that would be likely to render the individual unable to complete the study Hypersensitivity to HMG-CoA reductase inhibitors Poor mental function, drug or substance abuse, or unstable psychiatric illnesses that may interfere with optimal participation in the study Treatment with another investigational drug within 30 days prior to Visit 1 Alcohol consumption >14 drinks per week Phytosterol/phytostanol-containing products including margarines within 2 weeks History of CHD, peripheral vascular disease, cerebrovascular disease, CHF, or uncontrolled arrhythmias Creatinine >1.5 mg/dL, nephrotic syndrome, or other renal disease Fasting plasma glucose (FPG) >126 mg/dL or history of diabetes Abnormal TSH
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dilated Cardiomyopathy Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-II congestive heart failure History of Stage C-D heart failure with EF ≤ 40% during the course of the disease Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant) Age > 18 yrs  Cardiomyopathy due to one of the following Ischemic heart disease Primary valvular lesion Hypertrophic cardiomyopathy Cardiac resynchronization within the last 3 months Transaminase values > 2.5 x upper limit of normal or history of liver disease Diagnosis of diabetes mellitus by Diabetes previously diagnosed per patient history or more fasting glucose values > 125 mg/dl Current NYHA class III or IV heart failure
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus HbA1c at the beginning of the trial between 8,5% and 10% Age: 18-50 years BMI <30 kg/m2 (due to limited MR diameter) Normal routine lab tests (blood cell count, kidney, liver, pancreas, thyroid and neuromuscular function) Availability within the local area throughout the study Ability to understand and sign the consent forms  Current smoking Present drug treatment Contraindications for MRS studies: claustrophobia and metalliferous implants Pregnancy HIV or Hepatitis acute disease 2 weeks previous to the examination Heart disease Hypertension (RR>140/95) Liver disease Kidney disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Coronary Artery Disease Age: Males ≥ 50 years; Females ≥55 years with: History of diabetes mellitus (prior documentation of fasting glucose ≥ 126 mg/dl or hemoglobin A1C > 6.5%), either type 1 or type 2, documented for at least 3 years and on medication for at least one year. 2. Age: Males ≥ 40 years; Females ≥45 years with: History of diabetes mellitus (prior documentation of fasting glucose ≥ 126 mg/dl or hemoglobin A1C > 6.5%), either type 1 or type 2, documented for at least 5 years and on medication for at least one year. 3. The patient or legally authorized representative must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board  Known coronary artery disease (stenosis >70%, history of myocardial infarction, or angina) 2. Symptomatic cerebral vascular disease (history of TIA, CVA, or cerebrovascular [carotid or cerebral arteries] revascularization) 3. Symptomatic peripheral vascular disease (history of claudication, amputation, or peripheral [including renal arteries] arterial revascularization) 4. Treatment with any other investigational drug within the previous 30 days 5. Any therapy or condition that would pose a risk to the patient or make it difficult to comply with study requirements. 6. Pregnant and/or lactating women, and women of child bearing potential not using acceptable means of contraception. Women of childbearing potential must be using adequate measures of contraception (as determined by the Investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. Women of childbearing potential must have a negative pregnancy test at screen. 7. Any life threatening condition/significant co-morbidity such that primary screening is inappropriate. -
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 25.0-60.0,  Metabolic Syndrome X Participants must meet 3 of the following BMI ≥30 kg/m2 HDL Cholesterol of <40 Triglycerides >150 mg/dl Fasting blood glucose >100 mg/dl Blood pressure >130/85 mm Hg Total Cholesterol of >200 mg/dl LDL Cholesterol of >160 mg/dl Interleukin 6 (IL-6) >5pg/mL  Morbidly obese: BMI >40 kg/m2 Taking any cholesterol-lowering medications 30 days prior to the start of enrollment and during the course of the study Enrolled in another clinical study in the past 6 months Pregnant, actively infected, on medication that interfered with healing (for example, steroids), were inflicted with systemic disease such as AIDS, HIV, active hepatitis or active malignancy (clinical signs within the past 5 years), or suffered from diabetes mellitus requiring daily insulin management
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Diabetes Mellitus Metabolic Syndrome Age greater than 30 years Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment with an oral hypoglycemic agent) or metabolic syndrome (defined as at least 3 of the following: 1. HDL less than 40 mg/dl for men or less than 50 mg/dl for women; 2. triglycerides greater than 150 mg/dl; 3. waist circumference greater than 40 inches for men and greater than 35 inches for women; 4. fasting glucose greater than 100 mg/dl) LDL cholesterol level less than 140 mg/dl Able to provide informed consent and complete study procedures  Change in therapy for glucose control or blood pressure less than 1 month before entry Hemoglobin A1C greater than 8.0% Renal insufficiency (serum creatinine greater than 1.6 mg/dl in men or 1.5 mg/dl in women Any investigational drug less than 1 month before entry Pregnancy (excluded by urine pregnancy test at study entry with ongoing use of reliable form of birth control) or lactation Liver function tests or serum creatinine kinase (CK) greater than 3 times upper limit of normal Clinically evident major illnesses or other problem that would make participation inappropriate Clinical history of symptomatic cholelithiasis Patients with coronary artery disease, peripheral arterial disease, or cerebral vascular disease will not be enrolled if they are currently taking lipid-lowering therapy Patients taking more than 40 mg/day of atorvastatin will be excluded. There is no "ceiling" level for patients taking fibrates
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Congenital Hypothyroidism Patients with congenital hypothyroidism due to thyroglobulin defective synthesis  Patients with another disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.167-999.0,  Heart Disease Patients who are at high risk for developing Cardiomyopathy or Congestive Heart Failure Patients two months of age and older  Those that are not willing to sign an informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Diabetes Mellitus Dyslipidemia Male and female between the ages of 20-75 years. 2. Female patients post menopausal, hysterectomized or if of childbearing potential using a reliable method of birth control. 3. Diagnosed with type 2 diabetes mellitus. 4. Fasting triglyceride ≧150 mg/dL ≦500 mg/dL or Non-HDL-C≧130,but≦200 mg/dL 5. Patients receiving stable antidiabetic treatment for 8 weeks before randomization (no change in the category of anti-diabetic agents, but the dose is adjustable). 6. All patients give written informed consent  A history of hypersensitivity to statins. 2. A history of rhabdomyolysis or hereditary muscle disorders. 3. Insulin-treated patients. 4. Patient with any conditions of acute or chronic pancreatitis. 5. Creatine kinase ≧3-fold upper limit of normal (ULN). 6. Patients with an estimated creatinine clearance (see note)≦30 ml/min or bilirubin ≧1.5-fold ULN, or chronic active hepatitis or liver function impairment (AST and ALT ≧3-fold ULN). 7. Overt proteinuria (repeat spot urine protein >300mg/dl by dipstick method). 8. Patients are taking cyclosporine. 9. A history of homozygous familial hypercholesterolemia or familial dysbetalipoproteinemia. 10. Patients with alcohol and drug abuse in past 3 years. 11. Serious or unstable medical or psychological conditions. 12. Hypothyroidism (TSH > 5 μIU/mL). 13. In the investigator's opinion, continuation in the study would be detrimental to the patient's well-being or might confound the clinical trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 10.0-16.0,  Type 1 Diabetes a current hemoglobin A1c(HbA1c) of >8.0% an average HbA1c of >8.0% during the past year diagnosed with Type 1 diabetes for at least one year reside in the metro Detroit tri-county area  severe mental impairment/thought disorder non-English speaking patient/parent co-morbid major medical condition such as cystic fibrosis
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Diabetes Mellitus, Type 1 Newly diagnosed type I diabetic patients Type I diabetes treated with basal-bolus regimen including 3 or more injections of Regular Human Insulin per day BMI, 26-40 kg/m2 HbA1c, 7.5%-10% Median 2Hrs post -prandial more than or equal to 140 mg/dl (more than or equal to 7.8 mmol/L) FPG more than or equal to 120 mg/dl (more than or equal to 6.7 mmol/L) Willingness to accept, and ability to inject insulin Glargine therapy  Pregnancy : The use of & during pregnancy is not contraindicated. However, in the absence of supportive data, Sanofi Aventis Pharmaceuticals cannot specifically recommend the use of Lantus in this patient population The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Type 1 Diabetes Pregnancy Signed informed consent Females with Type 1 diabetes for at least 5 years Diabetes onset < 21 years Lean at diabetes onset Insulin required from diagnosis Willing to undergo intravenous arginine tolerance tests  Inability to provide informed consent Any medical condition that would preclude safe conduct of the intravenous arginine A family history which includes three generations of family members with the diagnosis of diabetes mellitus Women with elevated serum creatinine as arginine is excreted by the kidneys
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Sympathetic Innervation Chronic Heart Failure Indication for CRT Stable optimal medication Non ischemic cardiomyopathy  Age less then 18 years Previous CRT Clinically relevant valvular heart disease or coronary artery disease Acute or chronic infection Untreated clinical hypo or hyperthyroidism or < 3 months euthyroidism Uncontrolled hypertension, defined as a systolic blood pressure > 160 mm Hg and/or a diastolic blood pressure > 95 mm Hg A concurrent medical condition (i.e. alcohol or drug abuse or a severe progressive extra cardiac disease or M. Parkinson) or is unlikely to comply with the protocol Participation to a previous protocol involving radioactivity in the past year Pregnancy